All studies
CompletedInterventional

Studying acute exacerbations and response: the COPD STARR 2 study

Chronic obstructive pulmonary disease (COPD) causes long-term breathing problems and sudden flare-ups where chest symptoms get worse. At present, doctors usually treat these flare-ups with both antibiotics and steroid tablets using a standard approach for everyone. However, steroid tablets do not benefit all patients and can cause unwanted side effects. The STARR 2 study is exploring a more personalised treatment plan. Researchers are checking whether measuring a type of white blood cell, called an eosinophil, can pinpoint who will truly benefit from steroids. Participants aged 40 and older who experience a flare-up will receive either standard treatment or personalised care guided by their blood test. Taking part lasts up to 12 months and involves health checks and breathing tests. The findings could help doctors tailor flare-up treatments more safely across the NHS.

At a glance

Status
Completed
Sponsor
University of Oxford
Enrolment target
228
Start
18 Sep 2017
Estimated completion
31 Dec 2019

What is this study about?

Chronic obstructive pulmonary disease (COPD) is a common lung condition that makes it hard to breathe. People with COPD often experience flare-ups, which are sudden periods where coughing, phlegm, and breathlessness become much worse. Doctors usually treat flare-ups with a standard combination of antibiotics and steroid tablets. While this routine helps many people, it takes a 'one-size-fits-all' approach. Steroids do not help every type of flare-up, and taking them repeatedly can cause troublesome side effects such as weakened bones, raised blood sugar, and mood changes.

Researchers believe treatment works best when it is tailored to the individual. Past research suggests that levels of a specific white blood cell, called an eosinophil, can show whether a flare-up will respond well to steroid tablets. A quick blood test can measure these cells. In this trial, doctors want to see if using this blood test to decide who gets steroids is better than simply giving steroids to everyone.

By comparing standard care with this targeted approach, the study aims to make COPD treatments smarter and safer. If successful, this research could prevent thousands of patients from taking powerful steroid medicines they do not need, while ensuring those who do need them get the right care quickly.

Key takeaways

  • The study tests whether blood tests can guide personalised flare-up care in COPD.
  • Targeted care aims to prevent patients from taking steroid tablets when they are not needed.
  • Open to adults aged 40 and over with COPD and a history of flare-ups.
  • Taking part lasts up to 12 months and involves up to five clinic visits.
  • Participation is voluntary, and you can withdraw at any point without affecting your care.

Who may be eligible?

You may be able to join this study if you are 40 or older and have a confirmed medical diagnosis of COPD based on breathing tests. You should be a current smoker or an ex-smoker with a history equivalent to smoking at least 20 cigarettes a day for 10 years (known as 10 pack-years). You also need to have had at least one flare-up in the past 12 months that required steroid tablets, antibiotics, or both.

You will not be eligible if you had asthma as a child, have active tuberculosis, or currently have lung cancer. The study is also not suitable for people taking regular, daily steroid tablets, or those whose sudden breathing trouble is caused by something else, such as pneumonia, a blood clot in the lungs, or heart problems. Women who are pregnant or breastfeeding cannot take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 40 or over.
  2. I have been diagnosed with COPD confirmed by a breathing test.
  3. I am a current smoker or have smoked in the past (at least 10 pack-years).
  4. I have had at least one COPD flare-up in the past year needing antibiotics or steroid tablets.
  5. I did not have asthma during my childhood.
  6. I do not take steroid tablets on a daily, long-term basis.
Answer every question to see your result.

What does participation involve?

If you take part, your involvement will last for up to 12 months and include up to five appointments. At these visits, you will complete health questionnaires, perform standard breathing tests, and provide small blood and urine samples.

If you experience a COPD flare-up during the study, you will contact the study team to receive a 14-day course of medication. You will be randomly placed by a computer into one of two groups. One group receives antibiotics and steroid tablets as usual. The other group receives antibiotics, but their blood test determines whether they receive steroid tablets or a dummy pill (placebo). After starting the medicine, the team will check on your recovery at day 14, day 30, and day 90. At 12 months, the team will do a final review of your medical notes.

Potential risks and benefits

You may not get any direct medical benefit from joining, but your participation could help improve future NHS treatments for people living with COPD. The breathing tests can sometimes trigger a brief cough or mild wheezing, and blood tests may cause temporary discomfort or a small bruise. Antibiotics and steroids can occasionally cause stomach upsets, rashes, or allergic reactions. Your safety is monitored throughout, and you are free to leave the study at any time without giving a reason and without your regular medical care being affected.

Locations (14)

  • Bicester Health Centre
    City only
    Bicester, England
  • Broadshires Health Centre
    Approximate
    Carterton, England
  • Montgomery House Surgery
    Approximate
    Bicester, England
  • White Horse Medical Practice
    City only
    Faringdon, England
  • Eynsham Medical Centre
    City only
    Witney, England
  • Windrush Medical Practice
    Unverified
    Whitney, England
  • Gladstone Surgery
    Unverified
    Chesham, England
  • Alchester Medical Group
    Unverified
    Bicester, England
  • Woodlands Medical Centre
    Unverified
    Didcot, England
  • Haddenham Medical Centre
    Unverified
    Aylesbury, England
  • Morland House Surgery
    Unverified
    Oxford, England
  • Norden House Surgery
    Unverified
    Buckingham, England

Common questions

What is an eosinophil?

An eosinophil is a type of white blood cell that helps fight infection and plays a role in swelling and inflammation. Testing its levels can show whether steroid tablets are likely to help your lungs.

Will I definitely receive antibiotics if I have a flare-up?

Yes. All participants who have a flare-up during the trial will receive antibiotics as part of their treatment.

What is a placebo?

A placebo is a dummy pill that looks and tastes identical to the real medication but contains no active medicine. It allows researchers to fairly test whether the steroid is truly making a difference.

Can I carry on using my regular inhalers?

Yes. You will continue to use your regular daily COPD inhalers as prescribed by your doctor throughout the trial.

What happens if my breathing gets worse during the trial?

Your safety comes first. If your symptoms worsen or you need extra medical help, the study team and your GP are available to adjust your treatment immediately.

How to find out more

ORTU Team

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.